The estimated Net Worth of Dominick Colangelo is at least $22.1 Million dollars as of 14 August 2024. Mr. Colangelo owns over 35,000 units of Vericel Corp stock worth over $10,419,697 and over the last 10 years he sold VCEL stock worth over $6,285,200. In addition, he makes $5,385,530 as President, Chief Executive Officer und Director at Vericel Corp.
Sign up
Mr. Colangelo VCEL stock SEC Form 4 insiders trading
Dominick has made over 35 trades of the Vericel Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 35,000 units of VCEL stock worth $105,700 on 14 August 2024.
The largest trade he's ever made was exercising 75,000 units of Vericel Corp stock on 4 October 2018 worth over $146,250. On average, Dominick trades about 20,281 units every 47 days since 2015. As of 14 August 2024 he still owns at least 238,437 units of Vericel Corp stock.
You can see the complete history of Mr. Colangelo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dominick Colangelo biography
Dominick C. Colangelo is the President, Chief Executive Officer, and Director of the Company. Mr. Colangelo is a director since March 2013, has served as Vericel's President and Chief Executive Officer since March 2013. Mr. Colangelo has more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas. During his tenure at Eli Lilly, he held positions as Director of Strategy and Business Development for Eli Lilly's Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with honors, from the Duke University School of Law.
What is the salary of Dominick Colangelo?
As the President, Chief Executive Officer und Director of Vericel Corp, the total compensation of Dominick Colangelo at Vericel Corp is $5,385,530. There are no executives at Vericel Corp getting paid more.
How old is Dominick Colangelo?
Dominick Colangelo is 56, he's been the President, Chief Executive Officer und Director of Vericel Corp since 2014. There are 10 older and 4 younger executives at Vericel Corp. The oldest executive at Vericel Corp is Robert Zerbe, 69, who is the Independent Chairman of the Board.
What's Dominick Colangelo's mailing address?
Dominick's mailing address filed with the SEC is 64 SIDNEY STREET, , CAMBRIDGE, MA, 02139.
Insiders trading at Vericel Corp
Over the last 10 years, insiders at Vericel Corp have traded over $9,831,645 worth of Vericel Corp stock and bought 890 units worth $10,297 . The most active insiders traders include Dominick Colangelo, Gerard J Michel und Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of $567,401. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth $18,700.
What does Vericel Corp do?
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
What does Vericel Corp's logo look like?
Complete history of Mr. Colangelo stock trades at Vericel Corp und Trevi Therapeutics
Vericel Corp executives and stock owners
Vericel Corp executives and other stock owners filed with the SEC include:
-
Dominick Colangelo,
President, Chief Executive Officer, Director -
Michael Halpin,
Chief Operating Officer -
Dominick C. Colangelo Esq.,
CEO, Pres & Director -
Michael Halpin,
Chief Operating Officer -
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.,
Chief Medical Officer -
Dr. Jonathan M. Hopper,
Chief Medical Officer -
Sean C. Flynn,
VP, Gen. Counsel & Sec. -
Robert Zerbe,
Independent Chairman of the Board -
Alan Rubino,
Independent Director -
Kevin McLaughlin,
Independent Director -
Heidi Hagen,
Independent Director -
Steven Gilman,
Independent Director -
Paul Wotton,
Independent Director -
Sandra Pennell,
Principal Financial Officer and Principal Accounting Officer -
Jonathan Siegal,
Principal Accounting Officer, VP & Corp. Controller -
Roland DeAngelis,
Sr. VP of Commercial Operations -
Heidi Hassen,
VP of HR -
Patrick J. Fowler,
Sr. VP of Corp. Devel. & Strategy -
Eric Burns,
Exec. Director of Financial Planning and Analysis & Investor Relations -
Joseph Anthony Mara Jr.,
CFO, Principal Accounting Officer & Treasurer -
Capital Management Lp Conso...,
-
Daniel Orlando,
Chief Operating Officer -
Gerard J Michel,
CFO and VP, Corp. Development -
Nelson M Sims,
Director -
Lisa Wright,
-
Joseph Anthony Jr Mara,
Chief Financial Officer -
Jonathan Siegal,
Principal Accounting Officer -
Jonathan Mark Hopper,
Chief Medical Officer -
Sean C. Flynn,
Chief Legal Officer